Showing 27,401 - 27,420 results of 43,973 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 0.66s Refine Results
  1. 27401
  2. 27402
  3. 27403
  4. 27404
  5. 27405

    Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE) by Ibrahima Gaye (8462562)

    Published 2025
    “…Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). …”
  6. 27406
  7. 27407

    Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) reverse methacholine airway hyperresponsiveness in rats by Mounira Tlili (12847046)

    Published 2022
    “…PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.…”
  8. 27408

    Effect of mini-dose ready-to-use liquid glucagon on preventing exercise-associated hypoglycemia in adults with type 1 diabetes by Ronnie Aronson (3705877)

    Published 2023
    “…</p> <p>Research Design and Methods</p> <p>Individuals initially participated in the in-clinic training phase for which they were randomized to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. …”
  9. 27409

    Effects of PD-0332991 on BSG cell lines derived from genetically engineered mouse models. by Kelly L. Barton (465812)

    Published 2013
    “…<p>Cells were treated with PD-0332991 for 48 hours before being harvested for MTT or BrdU assays to assess cell survival and proliferation, respectively. (A) MTT assays (left panel) show minimal cytotoxic activity at doses up to 5µM in cell lines derived from PDGF-B; Ink4a-ARF deficient BSGs. …”
  10. 27410
  11. 27411
  12. 27412
  13. 27413
  14. 27414
  15. 27415

    Comparison of lentiviral vector titration methods-2 by Martine Geraerts (20224)

    Published 2011
    “…A decrease in vector titer starting at 3 days post-transfection was evidenced by all methods. …”
  16. 27416

    Table 2_Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b.docx by Tao Wang (12008)

    Published 2025
    “…HBsAg reversion occurred in 26 patients, yielding a reversion rate of 15.03% (26/173). Among these 26 patients, 50% (13/26) experienced reversion within 24 weeks, and 80.77% within 48 weeks; thereafter, the number of reversions gradually decreased. …”
  17. 27417

    Table 1_Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b.docx by Tao Wang (12008)

    Published 2025
    “…HBsAg reversion occurred in 26 patients, yielding a reversion rate of 15.03% (26/173). Among these 26 patients, 50% (13/26) experienced reversion within 24 weeks, and 80.77% within 48 weeks; thereafter, the number of reversions gradually decreased. …”
  18. 27418

    Optimisation of read depth, DNA quantity, and unique alternate observation threshold. by Melinda L. Tursky (20790436)

    Published 2025
    “…<p>A: The detection rate of reference standard variants ranging from 0.0008 to 0.1 VAF at 500-5,000 × depth. …”
  19. 27419
  20. 27420